SIGN UP FOR UPDATES!
Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
ENGLEMED
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BOOKS AND GIFTS THIS WAY!
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here
SEARCH THIS SITE
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
FreeDigitalPhotos
www.freedigitalphotos.net
FreeWebPhotos
www.freewebphoto.com
FROM OUR NEWS FEEDS
SARS-CoV-2 mutations 'do not increase transmissibility'
Thurs November 26th - None of the SARS-CoV-2 virus mutations that have been documented so far increase transmissibility in humans, a new study has shown. More
Midlife high blood pressure linked to elderly brain damage
Thurs November 26th - High blood pressure in middle age is associated with the development of more extensive brain damage when elderly, researchers report today. More
Activity can offset sedentary lifestyle - WHO says
Thurs November 26th - Exceeding the recommendations for weekly physical activity can offset the health harms associated with prolonged sitting, says new guidelines from the World Health Organisation. More
RECENT COMMENTS
On 09/10/2020 William Haworth wrote:
How long is recovery time after proceedure... on Ablation cuts atrial fibrillat...
On 04/08/2020 VICKY P ADAM wrote:
I would like to thank WORLD HERBS CLINIC for reve... on Medieval remedy for bacterial ...
On 29/07/2020 Amdre wrote:
When i read many blogs online about cure to HSV, a... on Medieval remedy for bacterial ...
On 14/07/2020 margret wrote:
I was diagnosed of ALS (amyotrophic lateral sclero... on Heart abnormalities revealed i...
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
OUR CLIENTS
THIS WEEK'S STORIES
ENGLEMED HEALTH NEWS

Drug trial for Parkinson hallucinations

Wednesday October 28th 2020

An anti-nausea drug is being tested to see if it can reduce the hallucinations which affect people with Parkinson’s disease.

The drug, ondansetron, is currently used to prevent nausea and vomiting in patients undergoing chemotherapy.

The charity Parkinson’s UK is working with University College London to run the £1 million, four year, trial which will include 216 patients. It is part of a larger initiative on novel drug development for Parkinson’s.

The trial will compare ondansetron against placebo for 12 weeks and be based at 20 to 25 NHS clinics across the UK. Visual and other types of hallucinations will be assessed after six and 12 weeks.

Dr Arthur Roach of Parkinson's UK said: “It’s vital we find better treatments for people with Parkinson's who have seen their hallucinations worsen at home and ondansetron offers much hope for them and their families. If successful, positive results from the trial could see this drug, which is already used in the NHS, quickly repurposed to become an available treatment in Parkinson’s.“

Lead Researcher, Professor Suzanne Reeves, added: “Finding treatments for hallucinations that are both effective and safe is an area of great unmet need. Ondansetron influences visual processing in the brain and its potential for treating visual hallucinations in Parkinson’s was first identified in small studies in the early 1990s.

“This trial will enable us to find out if ondansetron is effective and safe as a treatment and if it is, we could see clinicians prescribing an inexpensive drug with fewer side effects to people with Parkinson’s throughout the UK.”

Tags: Brain & Neurology | Pharmaceuticals | UK News

Printer friendly page Printer friendly page

Comment on this article:

Name:
Email:
Comment:
<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)
CATEGORIES